1 JANUARY – 31 DECEMBER 2024

SIGNIFICANT EVENTS DURING THE QUARTER 
 

• Spermosens carries out a rights issue of units of approximately SEK 22.7 million
• Kallelse till extra bolagsstämma i Spermosens AB (publ) för beslut om emission
• Spermosens recruits first couple for clinical study on next-generation male fertility diagnostic product
• Spermosens receives notice of allowance for broad US patent covering JUNO-Checked technology
• Spermosens signs memorandum of understanding for commercial partnership in Japan
• Spermosens reports strong progress in clinical study
• Spermosens reduces spending by focusing on clinical study and business development
• Announcement from the Extraordinary General Meeting of Spermosens AB (publ)
• Spermosens announces advancements in second-generation JUNO-Checked system
• Spermosens publishes information memorandum due to upcoming rights issue of units
• Spermosens' commercial strategy targets billion-dollar sperm bank market through global partnerships
• Spermosens publishes outcome in rights issue
• Spermosens announces positive results from ongoing clinical study
• Spermosens carries out directed issues of approx. MSEK 5.59, takes up credit facility of MSEK 1.00, and receives proposal of directed issues of approx. MSEK 0.39
• Spermosens year-end status update: Strong progress and promising outlook for 2025

 

SIGNIFICANT EVENTS AFTER THE END OF THE INTERIM PERIOD

• Spermosens announces relocation to a smaller office at Medicon Village
• Kallelse till extra bolagsstämma i Spermosens

 

 

FINANCIAL INFORMATION

		2024	2023	2024	2023
Amounts in SEK thousand		Q4	Q4	Full-Year	Full-Year
Net sales		–	–	–	–
Operating profit/loss		-2 373	-1 416	-9 163	-10 873
- Whereof activated work for own account		408	2 541	4 120	11 742
Cash and cash equivalents		659	4 492	659	4 492
Total Cash flow		530	-4 147	-3 833	3 940
Equity end of period		27 345	12 692	27 345	12 692
Balance sheet total		31 044	26 105	31 044	26 105
Equity/assets ratio,%		88	49	88	49
Liquidity ratio,%		47	43	47	43
No. of shares		283 607 120	41 193 676	283 607 120	41 193 676
Weighted average number of shares, adjusted for dilution effect (thousands)		283 607 120	41 193 676	187 569 007	38 086 723
Earnings per share, SEK		0,01	-0,04	-0,04	-0,32
Number of employees at end of period		3	7	3	7

 

 

CEO COMMENTS

2024 was a defining year for Spermosens. As male infertility continues to be a growing global challenge, we remain committed to advancing fertility diagnostics to support couples facing difficulties conceiving and becoming parents. The need for effective tools to assess sperm function during fertilization is well-established in reproductive medicine, and Spermosens is uniquely addressing this gap with our patented JUNO-Checked technology, the first-ever method to measure the binding capacity of sperm cells to the egg.

 

A significant milestone in 2024 was the launch of our clinical study at the Reproductive Medicine Center (RMC) in Malmö. This study is designed to demonstrate the diagnostic relevance of the JUNO-Checked technology and lay the foundation for future commercial partnerships. Recruitment has progressed well, and the first interim results are very encouraging. We observed a positive correlation between sperm binding capacity and fertilization outcomes, indicating that JUNO-Checked has the potential to improve fertility diagnostics.

 

Spermosens’ commercialization strategy is centered around licensing agreements with established partners, providing a cost-effective and scalable route to market. In 2024, we made significant progress in advancing our strategy. We signed a Memorandum of Understanding (MoU) with a well-established Japanese company to explore commercialization opportunities in Japan and strengthened our presence in the US through a partnership with ScanMed Partners, a firm specializing in identifying commercialization opportunities for Scandinavian healthcare technologies.

 

Discussions with potential partners in Europe, the US, and Asia have progressed, and we are encouraged by the strong interest from the sperm bank sector. The global sperm bank market, valued at approximately USD 5 billion, is actively seeking innovative solutions to enhance donor selection and improve success rates in assisted reproduction. Our technology presents a unique opportunity to meet these needs by improving donor screening, enhancing sperm quality, and improving IVF success rates.

 

In parallel with our clinical and commercial advancements, we have made key technical improvements to the JUNO-Checked system. The second-generation system features an optimized workflow and shorter readout times, enhancing its potential for clinical adoption. These advancements further strengthen our discussions with potential partners by demonstrating improved usability of our solution in clinical and laboratory settings.

 

We successfully conducted a rights issue and a directed issue late 2024, which we are very pleased about. These steps, together with significant cost reductions, strengthen our financial position and allow us to pursue our ambitious goals.

 

We are now looking forward to an exciting and eventful year, with value-triggering results from the clinical study and advancements in our partnership discussions. Solid clinical evidence is critical in demonstrating the diagnostic relevance of JUNO-Checked and is pivotal for securing commercial partnerships. Our ambition is to complete the clinical study in 2025, which we believe will demonstrate that JUNO-Checked is a key solution for improving fertility treatment. We will continue to share interim results from the clinical study on a regular basis, and we expect to see further engagement with potential partners in Europe, the US and Asia, as we aim to bring our solution to IVF clinics and sperm banks worldwide.

 

With a strong scientific foundation, a defined commercialization strategy, and the clinical evidence we expect to gather in 2025, we are well-positioned to build significant value for our shareholders and future patients. We are confident that this year will bring us closer to our goal of bringing transformative fertility diagnostics to market.

 

I would like to extend my sincere gratitude to our shareholders, employees and partners for their dedication and support. We have made great progress, and I look forward to an exciting and eventful year.

 

Tore Duvold, CEO of Spermosens AB